Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?

Published:2023-09-28 Issue:10 Volume:23 Page:1201-1210
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Darvishi Ali¹,Abdi Dezfouli Ramin¹,Fazaeli Aliakbar²,Daroudi Rajabali²³,Zandieh Narges⁴

Affiliation:

1. Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

2. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

3. National Center for Health Insurance Research, Tehran, Iran

4. Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

Funder

Ministry of Health

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2023.2263167

Reference44 articles.

1. Depression, hopelessness and social support among breast cancer patients: in highly endogamous population;Bener A;Asian Pacific J Cancer Prev,2017

2. Globocan. Breast. (2018). http://gco.iarc.fr/today/data/factsheets/cancers/20-Breastfact-sheet.pdf

3. Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Lyon: IARC Scientific Publication; 2007.

4. Awareness and current knowledge of breast cancer

5. Sh R. The costs of breast cancer in the US [Internet]. 2015 [Updated 2015 Nov 16].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP